SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-265618"
 

Search: id:"swepub:oai:DiVA.org:uu-265618" > Investigating Nephr...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Nilsson, AnnaUppsala universitet,Institutionen för farmaceutisk biovetenskap (author)

Investigating Nephrotoxicity of Polymyxin Derivatives by Mapping Renal Distribution Using Mass Spectrometry Imaging

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2015-09-04
  • American Chemical Society (ACS),2015
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-265618
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-265618URI
  • https://doi.org/10.1021/acs.chemrestox.5b00262DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Colistin and polymyxin B are effective treatment options for Gram-negative resistant bacteria but are used as last-line therapy due to their dose-limiting nephrotoxicity. A critical factor in developing safer polymyxin analogues is understanding accumulation of the drugs and their metabolites, which is currently limited due to the lack of effective techniques for analysis of these challenging molecules. Mass spectrometry imaging (MSI) allows direct detection of targets (drugs, metabolites, and endogenous compounds) from tissue sections. The presented study exemplifies the utility of MSI by measuring the distribution of polymyxin B1, colistin, and polymyxin B nonapeptide (PMBN) within dosed rat kidney tissue sections. The label-free MSI analysis revealed that the nephrotoxic compounds (polymyxin B1 and colistin) preferentially accumulated in the renal cortical region. The less nephrotoxic analogue, polymyxin B nonapeptide, was more uniformly distributed throughout the kidney. In addition, metabolites of the dosed compounds were detected by MSI. Kidney homogenates were analyzed using LC/MS/MS to determine total drug exposure and for metabolite identification. To our knowledge, this is the first time such techniques have been utilized to measure the distribution of polymyxin drugs and their metabolites. By simultaneously detecting the distribution of drug and drug metabolites, MSI offers a powerful alternative to tissue homogenization analysis and label or antibody-based imaging.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Goodwin, Richard J. A.AstraZeneca R&D, Drug Safety & Metab, Innovat Med, Cambridge CB4 0WG, England. (author)
  • Swales, John G.AstraZeneca R&D, Drug Safety & Metab, Innovat Med, Cambridge CB4 0WG, England. (author)
  • Gallagher, RichardAstraZeneca R&D, Oncol DMPK, Innovat Med, Macclesfield SK10 4TF, Cheshire, England. (author)
  • Shankaran, HarishAstraZeneca R&D, Drug Safety & Metab, Innovat Med, Waltham, MA 02451 USA. (author)
  • Sathe, AbhishekAstraZeneca R&D, Infect DMPK, Innovat Med, Waltham, MA 02451 USA. (author)
  • Pradeepan, SelviAstraZeneca R&D, Infect DMPK, Innovat Med, Waltham, MA 02451 USA. (author)
  • Xue, AixiangAstraZeneca R&D, Drug Safety & Metab, Innovat Med, Waltham, MA 02451 USA. (author)
  • Keirstead, NatalieAstraZeneca R&D, Drug Safety & Metab, Innovat Med, Waltham, MA 02451 USA. (author)
  • Sasaki, Jennifer C.AstraZeneca R&D, Drug Safety & Metab, Innovat Med, Waltham, MA 02451 USA. (author)
  • Andrén, Per E.Uppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)perandre (author)
  • Gupta, AnshulAstraZeneca R&D, Infect DMPK, Innovat Med, Waltham, MA 02451 USA.;AstraZeneca, Waltham, MA 02451 USA. (author)
  • Uppsala universitetInstitutionen för farmaceutisk biovetenskap (creator_code:org_t)

Related titles

  • In:Chemical Research in Toxicology: American Chemical Society (ACS)28:9, s. 1823-18300893-228X1520-5010

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view